Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4

Fig. 3

FKBPL overexpression induces differentiation of stem cell-like holoclones to more differentiated meroclones/paraclones in MCF-7. FKBPL overexpression or AD-01/ALM201 treatment downregulates DLL4 and Notch4 ICD expression in MCF-7 cells. a A reduction in the number of holoclones formed and a concomitant increase in the number of more differentiated, meroclone and paraclone colonies, following stable FKBPL overexpression (D2), was observed in MCF-7. b Western blot of cell lysates from MDA-MB-231 cells stably overexpressing FKBPL (A3) probed for DLL4, FKBPL and GAPDH (representative blot in inset). c Real-time qPCR analysis of DLL4 mRNA levels in MCF-7 vs. D2 cells. d Western blot of cell lysate from MCF-7 cells treated with AD-01 (100 nM) and probed for DLL4, Notch4ICD (double band) and GAPDH (representative blot in inset). Relative protein expression was quantified using ImageJ. e Real-time qPCR analysis of DLL4 mRNA levels in MCF-7 cells treated with ALM201 (100 nM). The difference in gene expression was presented as a fold change relative to the expression of the housekeeping genes, GAPDH and ß –Actin. Data points are mean ± SEM. n ≥ 3. * p < 0.05, ** p < 0.01, ***p < 0.01 (t-test). ICD – intracellular domain

Back to article page